Cardiff Oncology disclosed positive Phase II data for onvansertib in RAS‑mutated metastatic colorectal cancer at the same time its CEO and CFO resigned, prompting a sharp market reaction and a two‑day share collapse. Company filings named Mani Mohindru as interim CEO and promoted an internal finance officer to chief accounting officer while the board searches for permanent replacements. Investors cut Cardiff’s market capitalization roughly in half amid concern that the leadership transition could complicate late‑stage planning despite the trial readout. Analysts noted the board appears to be repositioning the company for late‑stage development with new management experienced in later‑phase programs; sponsors and partners will watch for clarity on regulatory strategy and Phase III initiation timing.